Trial · NCT00482703
Results by group98
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 98
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 100 mg QD Starting Dose Cohort | MCyR | 45 | 95% Confidence Interval 16.7 to 76.6 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 100 mg QD Starting Dose - Imatinib-resistant | MCyR | 29 | 95% Confidence Interval 3.7 to 71.0 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 100 mg QD Starting Dose - Imatinib-intolerant | MCyR | 75 | 95% Confidence Interval 19.4 to 99.4 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 50 mg BID Starting Dose Cohort | MCyR | 92 | 95% Confidence Interval 61.5 to 99.8 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 50 mg BID Starting Dose - Imatinib-resistant | MCyR | 86 | 95% Confidence Interval 42.1 to 99.6 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 50 mg BID Starting Dose - Imatinib-intolerant | MCyR | 100 | 95% Confidence Interval 47.8 to 100.0 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 100 mg QD Starting Dose Cohort | CCyR | 27 | 95% Confidence Interval 6.0 to 61.0 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 100 mg QD Starting Dose - Imatinib-resistant | CCyR | 14 | 95% Confidence Interval 0.4 to 57.9 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 100 mg QD Starting Dose - Imatinib-intolerant | CCyR | 50 | 95% Confidence Interval 6.8 to 93.2 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 50 mg BID Starting Dose Cohort | CCyR | 58 | 95% Confidence Interval 27.7 to 84.8 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 50 mg BID Starting Dose - Imatinib-resistant | CCyR | 43 | 95% Confidence Interval 9.9 to 81.6 | percentage of participants |
| Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 | Dasatinib 50 mg BID Starting Dose - Imatinib-intolerant | CCyR | 80 | 95% Confidence Interval 28.4 to 99.5 | percentage of participants |
| Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment | Dasatinib 100 mg QD Starting Dose Cohort | AEs (symptoms/signs and laboratory abnormalities) | 11 | participants | |
| Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment | Dasatinib 50 mg BID Starting Dose Cohort | AEs (symptoms/signs and laboratory abnormalities) | 12 | participants | |
| Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment | Dasatinib 100 mg QD Starting Dose Cohort | SAEs (symptoms/signs and laboratory abnormalities) | 4 | participants | |
| Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment | Dasatinib 50 mg BID Starting Dose Cohort | SAEs (symptoms/signs and laboratory abnormalities) | 6 | participants | |
| Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment | Dasatinib 100 mg QD Starting Dose Cohort | Deaths | 0 | participants | |
| Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment | Dasatinib 50 mg BID Starting Dose Cohort | Deaths | 0 | participants | |
| Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment | Dasatinib 100 mg QD Starting Dose Cohort | AEs that led to discontinuation | 0 | participants | |
| Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment | Dasatinib 50 mg BID Starting Dose Cohort | AEs that led to discontinuation | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00482703/results